about
Diversity-oriented synthesis yields novel multistage antimalarial inhibitorsIdentification and functional validation of the novel antimalarial resistance locus PF10_0355 in Plasmodium falciparumIn vivo transcriptome of Plasmodium falciparum reveals overexpression of transcripts that encode surface proteins.Diversity-Oriented Synthesis Yields a Novel Lead for the Treatment of Malaria.Diversity-oriented synthesis-facilitated medicinal chemistry: toward the development of novel antimalarial agentsGenetic surveillance detects both clonal and epidemic transmission of malaria following enhanced intervention in SenegalHarnessing evolutionary fitness in Plasmodium falciparum for drug discovery and suppressing resistanceDiversity-oriented synthesis probe targets Plasmodium falciparum cytochrome b ubiquinone reduction site and synergizes with oxidation site inhibitors.Aminoazabenzimidazoles, a novel class of orally active antimalarial agents.Triaminopyrimidine is a fast-killing and long-acting antimalarial clinical candidate.Human cerebral malaria and Plasmodium falciparum genotypes in Malawi.Clinical Sequencing Uncovers Origins and Evolution of Lassa VirusProbing the Azaaurone Scaffold against the Hepatic and Erythrocytic Stages of Malaria Parasites.Sequence-based association and selection scans identify drug resistance loci in the Plasmodium falciparum malaria parasite.Intramolecular Diaza-Diels-Alder Protocol: A New Diastereoselective and Modular One-Step Synthesis of Constrained Polycyclic Frameworks.The cytoplasmic prolyl-tRNA synthetase of the malaria parasite is a dual-stage target of febrifugine and its analogs.A broad analysis of resistance development in the malaria parasiteNew paradigms for understanding and step changes in treating active and chronic, persistent apicomplexan infections.Genome-wide SNP genotyping highlights the role of natural selection in Plasmodium falciparum population divergence.Polymorphism in dhfr/dhps genes, parasite density and ex vivo response to pyrimethamine in Plasmodium falciparum malaria parasites in Thies, Senegal.Plasmodium falciparum Cyclic Amine Resistance Locus (PfCARL), a Resistance Mechanism for Two Distinct Compound Classes.Changes in drug sensitivity and anti-malarial drug resistance mutations over time among Plasmodium falciparum parasites in Senegal.Genome-Wide Association Studies of Drug-Resistance Determinants.Exploring the 3-piperidin-4-yl-1H-indole scaffold as a novel antimalarial chemotype.SNP genotyping identifies new signatures of selection in a deep sample of West African Plasmodium falciparum malaria parasitesA genome-wide map of diversity in Plasmodium falciparum.Quantitative Proteomic Profiling Reveals Novel Plasmodium falciparum Surface Antigens and Possible Vaccine Candidates.Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics.Identification of Collateral Sensitivity to Dihydroorotate Dehydrogenase Inhibitors in Plasmodium falciparum.The Adaptive Proline Response in P. falciparum Is Independent of PfeIK1 and eIF2α SignalingOpen-source discovery of chemical leads for next-generation chemoprotective antimalarialsIn vitro selection predicts malaria parasite resistance to dihydroorotate dehydrogenase inhibitors in a mouse infection model
P50
Q27861934-01B3975F-4B3D-4D15-B40E-E1785CBB5682Q28477846-77DD3FBA-F25E-457B-8C55-E4799931BC36Q30984141-507207C3-00AE-47CE-BCD1-B8866584388CQ34157359-C19A0AE3-2EB8-4F72-8C2E-DF5085968A18Q34394236-69B4A1A3-FEF5-4C88-BBAA-216188C9325DQ34674130-80CE5BB6-0F17-41EF-803E-983B4CCB47A9Q35079297-B49E9C54-C671-4C0E-921E-6C8175B69B25Q35163309-817C2E49-4742-452C-BC07-F9D1F0A82F29Q35184671-B087F57E-6705-4B42-9658-00E6FBEC3DE8Q35311620-57809E4D-B3B0-4103-AACE-318F6C696B78Q35809092-BA658007-A943-4224-B0C0-D4CD2AAE0CF6Q35957928-C8F92DE9-5DA5-446D-9098-27FA21576DD4Q36107459-6DE3C3AB-C1AC-4CAF-A262-03CAF1E1342EQ36167604-8B003E9A-D832-4FDF-9282-1765ABF521F3Q36229686-4A3B8391-D071-4619-ABA3-08428A744EB5Q36362906-BCC951CB-F530-41CB-BB9C-09336A74F4C1Q37017711-5AAD5E01-6374-48DF-AC42-AF07BCBC5214Q37093155-7CEF638E-2AE5-43C1-B803-D26829E2FCE5Q37105924-B60E4F7A-7D0E-44C9-B09F-E1332F000EC4Q37390524-18CD1518-E0F8-4ADE-8F28-27D5769E2618Q37414137-8860D37E-BB77-442D-A0B2-C4989BC7B570Q37583332-676BFAE4-3D31-4CDB-A3F9-D50DB8AD9D43Q39126869-F8CE6CEC-F60E-4C5E-8778-DD803A28EC8FQ41040220-BCF1DBA1-FCEF-4725-A976-BE2222B08596Q42424354-1ED2119E-1B48-40DB-B355-56144F0454A3Q44045368-267EDAE7-9F78-402B-87C2-93D290D0ACC3Q47377549-D36314C5-F060-4A8B-BD9F-DBDB93439B23Q48021791-3D03E4CE-FBE0-4602-BB7D-FEDAA286EC26Q48022169-06A9A8D3-6D70-4D27-BB18-4748443B6D53Q63384432-AA99E4EE-B6C8-4F0E-B52E-B3F6362B9E33Q64356851-D72938B4-0C04-4C03-B9AE-21BE3EA96612Q91697590-1527316B-1B0B-4989-A6DB-6F8EDC08A470
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Amanda K Lukens
@ast
Amanda K Lukens
@en
Amanda K Lukens
@es
Amanda K Lukens
@nl
Amanda K Lukens
@sl
type
label
Amanda K Lukens
@ast
Amanda K Lukens
@en
Amanda K Lukens
@es
Amanda K Lukens
@nl
Amanda K Lukens
@sl
prefLabel
Amanda K Lukens
@ast
Amanda K Lukens
@en
Amanda K Lukens
@es
Amanda K Lukens
@nl
Amanda K Lukens
@sl
P106
P21
P31
P496
0000-0002-9560-7643